会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 22. 发明授权
    • Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
    • 适用于治疗对多巴胺D3受体调节作出反应的疾病的杂环化合物
    • US08470810B2
    • 2013-06-25
    • US12868480
    • 2010-08-25
    • Karla DrescherAndreas HauptLiliane UngerSean C. TurnerWilfried BrajeRoland GrandelChristophe HenryGisela BackfischArmin BeyerbachWilfried Lubisch
    • Karla DrescherAndreas HauptLiliane UngerSean C. TurnerWilfried BrajeRoland GrandelChristophe HenryGisela BackfischArmin BeyerbachWilfried Lubisch
    • A61K31/397C07D413/02
    • C07D413/14C07D205/04C07D207/09C07D211/28C07D401/04C07D401/12C07D403/04C07D405/12C07D409/12C07D413/10C07D413/12
    • The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH2 or CHR3; R1 is H, C,-C6-alkyl, C,-C6-alkyl substituted by C3-C6-cycloalkyl, C1-C6-hydroxyalkyl, fluorinated C,-C6-alkyl, C3-C6-cycloalkyl, fluorinated C3-C6-cycloalkyl, C3-C6 alkenyl, fluorinated C3-C6-alkenyl, formyl, acetyl or propionyl; R2, R3 and R4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one or more substituents selected from halogen, methyl, methoxy and CF3; E is NR5 or CH2, wherein R5 is H or C1-C3-alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR8, where R8 is H, C1-C4-alkyl, fluorinated C1-C4-alkyl, C1-C4alkylcarbonyl or fluorinated C1-C4-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents Ra, wherein the variable Ra has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
    • 本发明涉及式(I)化合物,其中n为0,1或2; G是CH 2或CHR 3; R 1是被C 3 -C 6 - 环烷基取代的C 1 -C 6 - 烷基,C 1 -C 6 - 烷基,C 1 -C 6羟基烷基,氟化C 1 -C 6 - 烷基,C 3 -C 6环烷基,氟化C 3 -C 6 - 环烷基,C3-C6烯基,氟化C3-C6-烯基,甲酰基,乙酰基或丙酰基; R2,R3和R4彼此独立地为H,甲基,氟甲基,二氟甲基或三氟甲基; A是可以被一个或多个选自卤素,甲基,甲氧基和CF 3的取代基取代的亚苯基,亚吡啶基,亚嘧啶基,吡嗪基,哒嗪基或噻吩基; E是NR5或CH2,其中R5是H或C1-C3-烷基; Ar是选自苯基,5或6元杂芳族基团的环状基团,其包含选自N,O和S的环成员1,2或3个杂原子和与饱和或不饱和5 - 或6-元碳环或杂环,其中杂环包含作为环成员1,2或3个选自N,O和S的杂原子和/或1,2或3个各自独立地选自NR8的含杂原子的基团,其中 R8是H,C1-C4-烷基,氟化C1-C4-烷基,C1-C4烷基羰基或氟化C1-C4-烷基羰基,其中环状基团Ar可以带有1,2或3个取代基Ra,其中变量Ra具有 在权利要求和说明书中给出的含义; 和其生理学耐受的酸加成盐。 本发明还涉及式I化合物或其药学上可接受的盐在制备用于治疗易受多巴胺D3受体配体治疗的医学疾病的药物组合物中的用途。
    • 26. 发明申请
    • PYRIMIDINE COMPOUNDS AND USE THEREOF
    • 吡嗪化合物及其用途
    • US20110118232A1
    • 2011-05-19
    • US12842776
    • 2010-07-23
    • Hervè GenesteAndreas HauptWilfried BrajeWilfried LubischGerd Steiner
    • Hervè GenesteAndreas HauptWilfried BrajeWilfried LubischGerd Steiner
    • A61K31/554C07D403/14A61K31/496C07D413/14A61K31/538C07D417/14A61K31/5415A61K31/551A61K31/55A61P25/00A61P25/18A61P25/24
    • C07D417/12C07D401/12C07D413/12
    • The invention relates to novel pyrimidine compounds of general formula (I), in which: A represents a group C═W or CRfRg; B represents a chemical bond or a group CRhRi; X represents O, S, a group N—Rk or a group CRmRn; D represents C═O or a chemical bond; E represents a linear or branched 2- to 10-membered alkylene chain that, as members of a chain, can have 1 or 2 non-adjacent heteroatom group(s) K, which is selected among O, S, S(O), S(O)2 and N—Rp and which can comprise a carbonyl group and/or a cycloalkanediyl group and/or a double or triple bond; W represents oxygen or sulfur; Z, together with the carbon atoms, to which it is bound, represents a condensed, optionally substituted 5-, 6- or 7-membered carbocyclic compound or heterocyclic compound that has 1, 2, 3 or 4 heteroatoms, which are selected among N, O and S; J represents CH2, CH2—CH2 or CH2—CH2—CH2; M represents CH or N; Y represents CH2, CH2—CH2 or CH2—CH2—CH2 or M-X, together, represent CH═C or CH2—CH═C; n is 0 or 1, and; Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rk, Rp, R1, R2, R3, R4, R5 and R6 have the meanings cited in the claims and in the description. The invention also relates to the physiologically compatible acid addition salts of the aforementioned compounds, and to the use of these compounds of general formula (I) and of the physiologically compatible acid addition salts of compounds (I) for producing a pharmaceutical agent for treating diseases, which respond to the influence of dopamine D3 receptor antagonists or agonists.
    • 本发明涉及通式(I)的新型嘧啶化合物,其中:A代表基团C = W或CRfRg; B表示化学键或CRhRi基; X表示O,S,基团N-Rk或基团CRmRn; D表示C = O或化学键; E表示直链或支链的2-至10-元亚烷基链,其作为链的成员可以具有1或2个不相邻的杂原子K,其选自O,S,S(O), S(O)2和N-Rp,并且其可以包含羰基和/或环烷二基和/或双键或三键; W表示氧或硫; Z与其结合的碳原子一起代表具有1,2,3或4个杂原子的缩合的,任选取代的5-,6-或7-元碳环化合物或杂环化合物,其选自N ,O和S; J表示CH 2,CH 2 -CH 2或CH 2 -CH 2 -CH 2; M表示CH或N; Y表示CH 2,CH 2 -CH 2或CH 2 -CH 2 -CH 2或M-X,一起表示CH = C或CH 2 -CH = C; n为0或1, Ra,Rb,Rc,Rd,Re,Rf,Rg,Rh,Ri,Rk,Rp,R1,R2,R3,R4,R5和R6具有权利要求书和说明书中引用的含义。 本发明还涉及上述化合物的生理上相容的酸加成盐,以及这些化合物(I)的化合物和化合物(I)的生理上相容的酸加成盐在制备用于治疗疾病的药剂中的用途 ,其响应于多巴胺D3受体拮抗剂或激动剂的影响。